• Policy
• There were no applications for Ultomiris·Soliris benefits
• by Lee, Hye-Kyung Jan 6, 2022 06:09am

• Policy
• Companies obtain generic for exclusivity in proportion
• by Lee, Tak-Sun Jan 6, 2022 06:08am

• Policy
• Request for non-reimbursed use of Pahtension in Loop's pts
• by Lee, Hye-Kyung Jan 6, 2022 06:08am

• Policy
• ‘Lowest-ever’ number of drugs approved in 4 years
• by Lee, Tak-Sun Jan 5, 2022 05:59am

• Policy
• Combination drugs of PPI+ antacid have also been released
• by Lee, Tak-Sun Jan 5, 2022 05:57am

• Policy
• Recovery Action held by the Legislation/Judiciary Committee
• by Lee, Jeong-Hwan Jan 4, 2022 05:56am

• Policy
• President Moon "will make all efforts to return to normalcy"
• by Lee, Jeong-Hwan Jan 4, 2022 05:56am

• Policy
• Minister Kwon said he would develop vaccines and txs
• by Kim, Jung-Ju Jan 4, 2022 05:55am

• Policy
• Additional contracts for COVID-19 PO tx are under discussion
• by Kim, Jung-Ju Jan 4, 2022 05:55am

• Policy
• Changes in Benefit standards such as diabetes drugs
• by Kim, Jung-Ju Dec 31, 2021 05:50am